Abstract
Non-invasive prenatal testing (NIPT) for common fetal aneuploidies using circulating cell free DNA in maternal plasma has been widely adopted in clinical practice for its sensitivity and accuracy. However, the detection of subchromosomal abnormalities or monogenetic variations showed no cost-effectiveness or satisfactory accuracy. Here we developed an assay, the goodness-of-fit and graphical analysis of polymorphic sites based non-invasive prenatal testing (GGAP-NIPT), to simultaneously detect fetal chromosomal/subchromosomal and nucleotide level abnormalities. In each sample, fetal fraction was estimated using allelic counts of reference polymorphic sites and a robust linear regression model. Then the genotype of each polymorphic site was estimated using allelic goodness of fit test. Finally, monogenic mutations were detected using allelic wildtype and mutant counts of each target site, and chromosomal/subchromosomal abnormalities were identified by collective analysis of all target polymorphic sites. Such an analytic approach was highly accurate for detecting aneuploidies, microdeletions or microduplications and monogenic mutations for simulated samples with different fetal fractions and sequencing depths. Moreover, more than 93% of fetal monogenic mutations were correctly identified for target hotspot sites amplified using circulating or barcode-enabled single-molecule assays. With the aid of sample replicates, higher detection accuracy was observed. Through target polymorphic sites sequencing, all chromosomal/subchromosomal and monogenic abnormalities could be detected simultaneously, facilitating the extension of NIPT to an expanded panel of genetic disorders in a cost-effective manner.
Competing Interest Statement
A patent application has been filed relating to this work.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were retrieved from NIH sra database and only computation was done on the data. Therefore, we regard that it was exempted naturally.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding statement: none.
Adding results analyses of monogenic mutations amplified by cSMART or cfBEST techniques.
Data Availability
All data are provided upon request to gaos{at}whu.edu.cn.
